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Abstract
Background: In Africa, the wide genetic diversity of HIV has resulted in emergence of new strains, rapid spread of
this virus in sub-Saharan populations and therefore spread of the HIV epidemic throughout the continent.
Methods: To determine the prevalence of antibodies to HIV among a high-risk population in Gabon, 1098 and
2916 samples were collected from pregnant women in 2005 and 2008, respectively. HIV genotypes were evaluated
in 107 HIV-1-positive samples to determine the circulating subtypes of strains and their resistance to antiretroviral
drugs (ARVs).
Results: The seroprevalences were 6.3% in 2005 and 6.0% in 2008. The main subtype was recombinant CRF02_AG
(46.7%), followed by the subtypes A (19.6%), G (10.3%), F (4.7%), H (1.9%) and D (0.9%) and the complex
recombinants CRF06_cpx (1.9%) and CRF11_cpx (1.9%); 12.1% of subtypes could not be characterized. Analysis of
ARVs resistance to the protease and reverse transcriptase coding regions showed mutations associated with
extensive subtype polymorphism. In the present study, the HIV strains showed reduced susceptibility to ARVs
(2.8%), particularly to protease inhibitors (1.9%) and nucleoside reverse transcriptase inhibitors (0.9%).
Conclusions: The evolving genetic diversity of HIV calls for continuous monitoring of its molecular epidemiology
in Gabon and in other central African countries.
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Background
Human immunodeficiency virus type 1 (HIV-1) is the
main sexually transmitted infectious agent in the world,
affecting approximately 33 million people with 2.7 mil-
lion new infections each year [1]. Diseases associated
with HIV infection cause 2.0 million of deaths annually,
and about 19 million people have already died from this
cause. Most HIV-1 infections are observed in Africa,
where the widest genetic diversity has been described
[2]. Previous studies showed that the HIV-1 pandemic
originated in central Africa, where populations have
been in close contact with pure subtypes, unique and
complex recombinant forms and many unclassified
strains [3-6].
Studies in the past decade showed increasing genetic
diversity of HIV-1 in Gabon, central Africa [7-10]. In
2000, Makuwa et al. demonstrated a predominance of
subtype A (49%) in the general population, with a num-
ber of unclassified HIV-1 strains (13%) [8]. Two years
later, the CRF02_AG (26%) and complex recombinant
MAL-like lineage (19%) were found to be increasing
[10]. A recent study conducted in our laboratory showed
a predominance of CRF02_AG (57%) among manganese
miners [7]. However, a high proportion of subtypes
* Correspondence: mirdad.kazanji@pasteur.fr
1Unité de Rétrovirologie, Centre International de Recherches Médicales de
Franceville, Franceville BP 769, Gabon
Full list of author information is available at the end of the article
Caron et al. BMC Infectious Diseases 2012, 12:64
http://www.biomedcentral.com/1471-2334/12/64
© 2012 Caron et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.(30%) were found discordant, indicating a complex
genetic composition of these circulating HIV-1 strains
in Gabon. A further study from our laboratory con-
firmed stable circulation of CRF02_AG (63%) among
migrant populations, and for the first time, demon-
strated the presence of the complex recombinant form
CRF11_cpx [9].
The anti-HIV prevalence infection in the general
Gabonese population is difficult to determine. Although
HIV prevention programs and social conditions have
improved, only a few patients in the main cities have
free access to treatment in medical structures with the
capacity to treat sexually transmitted diseases [11].
Nevertheless, some studies have been conducted on the
resistance of HIV-1 to antiretroviral drugs (ARVs). A
study in Libreville, the capital of Gabon, showed emer-
ging resistance to nucleoside reverse transcriptase inhi-
bitors (NRTIs) during treatment for HIV-1 infection
[12]. Two other studies, conducted among untreated
population, identified only mutations associated with
subtype polymorphism and did not address susceptibility
to ARVs [7,9]. Data on HIV drug resistance-associated
mutations among untreated and treated population in
resource-limited settings such as Gabon are either
scarce or out of date.
To limit the propagation of HIV, native or transmitted
ARVs-resistant strains must be detected by continuous
monitoring of HIV-infected population at greatest risk.
In the absence of an effective vaccine against HIV, this
information is needed before new introduction of ARVs
in Africa. In order to evaluate the level of resistance to
ARVs in Gabon, we determined the anti-HIV prevalence
among pregnant women in the main cities to character-
ize the circulating subtypes and ARVs resistance-asso-
ciated mutations.
Methods
Area and population studied
Gabon occupies 26 7667 km
2 i nt h eG u l fo fG u i n e ao n
the Equator, with tropical forest covering three quarters
of the territory. The population is around 1.5 million,
73% of whom live in urban areas. Gabon is divided into
nine provinces, in which the main cities are: Libreville
(Estuaire), the capital of Gabon, in the northwest; Port-
Gentil (Ogooué-Maritime), the main harbor and eco-
nomic capital, in the west; Lambaréné (Moyen-Ogooué)
in the centre west; Oyem (Woleu-Ntem) in the north;
Makokou (Ogooué-Ivindo) in the northeast; Franceville
(Haut-Ogooué) in the southeast; Koulamoutou
(Ogooué-Lolo) in the centre east; Mouila (Ngounié) in
the centre and Tchibanga (Nyanga) in the south of the
country (Figure 1).
In 2005 and 2008, the retrovirology laboratory at the
International Centre for Medical Research of Franceville
(CIRMF) and the National Program to Fight Against
AIDS in Libreville conducted epidemiologic surveys of
pregnant women at their first antenatal examination or
first postnatal medical consultation, according to the
guidelines of the World Health Organization. The study
reported here was conducted in the main cities of the
nine provinces, thus representing the general population
of pregnant women in Gabon. The survey was con-
ducted by a multidisciplinary team, including physicians
from the Gabonese Ministry of Health. Anonymous
venous blood samples were collected by locally trained
health staff. Before testing, fully informed consent was
obtained from each woman and when women were
younger than 18 years, informed consent was obtained
from their parents. The samples were anonymous, but
age and geographic origin were retained. The study
obtained ethical clearance from the Gabonese public
health authorities and from the Gabonese scientific and
ethical committees.
A total of 1098 samples were collected in 2005 and
2916 samples in 2008. The mean age of the women was
24.5 ± 6.3 years (range, 14-44 years) in 2005 and 24.0 ±
6.4 years (range, 14-47 years) in 2008. To determine the
circulating subtypes and HIV-resistance to ARVs, sam-
ples were taken from 107 untreated HIV-1-infected
pregnant women aged 26.6 ± 6.4 years (range, 15-40
years) and included for molecular and phylogenetic ana-
lysis (data not shown). The women was selected on the
100 km
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Figure 1 Map of Gabon, central Africa, with provinces and
main cities. In grey, provinces; square, capital; circles, main cities.
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5.7 ± 6.3 log10 copies/mL; range, 4.0-7.3 log10 copies/
mL) in order to obviate failure of pol gene amplification.
Serological analysis
Plasma samples were separated from venous blood and
tested for the presence of antibodies to HIV-1 or HIV-2
by ELISA (Genscreen
® HIV-1/2 version 2, Biorad,
Marne la Coquette, France) and by a rapid test (Deter-
mine™ HIV-1/2, Abbott, Chicago, Illinois, USA),
according to the manufacturers’ instructions. Antibody
pattern was confirmed by western blot (New LAV Blot I
& II, BioRad, Marne la Coquette, France).
Molecular and phylogenetic analysis
RNA was extracted from plasma samples with a
QIAamp
® Viral RNA Mini Kit (Qiagen, Courtaboeuf,
France), and viral plasma RNA from HIV-positive sam-
ples was used to quantify the viral load (Generic HIV
Charge Viral, Biocentric, Bandol, France). In order to
determine the HIV subtypes and resistance-associated
mutations in protease (P) and reverse transcriptase (RT)
coding regions, pol gene targets of the main ARVs, were
amplified by the French National Agency for AIDS
Research consensus polymerase chain reaction (PCR)
technique (AC-11 Resistance Group, http://www.hiv-
frenchresistance.org).
HIV genotype was determined by local alignment of
partial pol sequences with the HIV Drug Resistance
Database of Stanford University http://dbpartners.stan-
ford.edu/RegaSubtyping/ and the HIV Database of the
National Institutes of Health http://www.hiv.lanl.gov/
content/sequence/BASIC_BLAST/basic_blast.html. To
confirm the assignment of HIV subtypes, reference
sequences obtained from the Los Alamos Sequence
Database and each Gabonese sequence were aligned
with the ClustalX program [13]. Manual corrections
were performed with the editor program of the MEGA
package, and phylogenetic relations were reconstructed
by the neighbor-joining method [14,15]. Bootstrapping
was performed with 1000 replicates.
Genotypic resistance to ARVs was defined according
to the 2011 Stanford Resistance Surveillance list of criti-
cal mutations http://hivdb.stanford.edu, the latest ver-
sions of the algorithms of the French National Agency
for AIDS Research and the International AIDS Society
http://www.iasusa.org. We confirmed our results by
determining transmitted ARVs resistance-associated
mutations in untreated women, as recommended by
Bennett et al. [16].
The newly sequenced HIV-1 strains are available
under GenBank accession numbers HQ541872-
HQ541944 and HQ541945-HQ541956.
Statistical analysis
Analyses were performed with Epi-Info (version 6.04 dfr,
ENSP-Epiconcept-InUS, 2001). A p value < 0.05 was
considered statistically significant. Results are expressed
as percentages (with 95% confidence intervals, CIs) and
odds ratios (ORs, with 95% CIs). Spearman correlation
coefficients were used to assess correlations between age
groups and anti-HIV prevalences. In order to avoid
selection bias in the molecular and phylogenetic analy-
sis, the Kruskal-Wallis test was used to compare contin-
uous variables among more than two groups; for age
groups by viral load and by city. No difference was
found (data not shown).
Results
Anti-HIV-1 prevalence
A n t i b o d i e st oH I Vw e r ef o u n di n6 9o f1 0 9 8p r e g n a n t
women tested in 2005 (6.3%; 95% CI, 4.9-7.7) and 174
of 2916 in 2008 (6.0%; 95% CI, 5.7-6.3) (Table 1). No
significant difference between 2005 and 2008 was
observed by age group or by province (data not shown).
During both years of the study, seroprevalences
increased by age group, with the highest among women
aged ≥ 36 years and the lowest among those aged ≤ 15
years. ELISA and western blotting indicated some HIV-
2 (n = 3, data not shown); no HIV-1 group O or N was
found in our population. HIV-2-infected women were
therefore excluded from the molecular studies.
HIV-1 subtypes and phylogenetic analysis
To evaluate the circulating HIV-1 subtypes, a > 1000
base-pair (bp) fragment (n = 95; range, 1004-1073 bp)
of the pol gene (P and RT coding regions) was
sequenced and phylogenetically analyzed (Figure 2A).
The long fragment of the pol gene could not be
obtained for 12 of the 107 HIV-1 samples, and analyzed
either the RT (n = 2; 785 bp) or the P (n = 10; range,
467-479 bp) coding region (Figure 2B and 2C).
Phylogenetic analysis of the pol gene showed wide
genetic diversity (Figure 2A, B and 2C). The genotypes
distribution is shown in Table 2. The main subtype
identified was CRF02_AG (n = 50, 46.7%), followed by
subtypes A (n = 21, 19.6%), G (n = 11, 10.3%), F (n = 5,
4.7%), H (n = 2, 1.9%) and D (n = 1, 0.9%). Complex
recombinant forms were also found, consisting of
CRF06_cpx and CRF11_cpx (n = 2, 1.9%). Thirteen sub-
types could not be characterized (12.1%).
ARVs resistance-associated mutations
Resistance to ARVs was genotyped in 107 HIV-1-posi-
tive samples. Data on mutations conferring resistance to
protease inhibitors (PIs), nucleoside reverse transcriptase
inhibitors (NRTIs) and non-NRTIs are summarized in
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minor or major genotypic resistance to ARVs, of which
3/107 (2.8%) were major mutations for resistance to PIs
(n = 2/107, 1.9%) and NRTIs (n = 1/107, 0.9%). No
major mutation for resistance to non-NRTIs was found.
The most frequent mutations observed in the P cod-
ing region corresponded to subtype polymorphism (data
not shown), while minor mutations, such as L10V/I,
V11I, E35G, A71T and T74S, were associated with low-
level resistance to some PIs (Table 2). L33F and M46I
indicate major PI resistance. In the RT coding region,
strong polymorphism was found (data not shown), with
common mutations such as V90I, V106I and E138A
(Table 2). A62V and T69S are minor mutations, which
Table 1 Prevalence of HIV by age among untreated pregnant women in Gabon in 2005 and 2008
Age group (years) 2005 2008
HIV+/tested % [95% CI] OR [95% CI] HIV+/tested % [95% CI] OR [95% CI]
≤ 15 1/41 2.4 [1.5-3.3] 0.4 [0.1-2.7] 3/106 2.8 [2.2-3.4] 0.5 [0.1-1.4]
16-25 35/619 5.7 [4.3-7.1] 0.8 [0.5-1.3] 78/1732 4.5 [3.7-5.3] 0.5 [0.4-0.7]
26-35 26/336 7.7 [6.1-9.3] 1.4 [0.9-2.3] 74/899 8.2 [7.2-9.2] 1.7 [1.3-2.4]
≥ 36 7/72 9.7 [7.9-11.5] 1.7 [0.7-3.8] 19/179 10.6 [9.5-11.7] 2.0 [1.2-3.3]
Total 69/1098 6.3 [4.9-7.7] - 174/2916 6.0 [5.7-6.3]-
HIV+/tested, number of HIV-positive and number of samples tested; CI, confidence interval; OR, odds ratio
Figure 2 Phylogenetic reconstructions for the assignment of HIV-1 subtypes, including the newly sequenced strain, in Gabon, central
Africa.( A) Phylogenetic tree of the partial pol gene constructed with a > 1000-bp fragment (n = 95; range, 1004-1073 bp); (B) phylogenetic tree
of reverse transcriptase coding region (n = 2; 785 bp); (C) phylogenetic tree of protease coding region (n = 10; range, 467-479 bp). Dataset of
sequences was compiled by combining reference sequences representative of groups M (each pure subtype and commonest CRFs), N and O.
The CPZ.US.85.CPZUS (AF103818) strain was used as outgroup to root the trees. The neighbor-joining method was used for the partial pol gene,
reverse transcriptase and protease coding regions. Confidence levels were estimated for 1000 replicates, and only bootstrapping values higher
than 60% were considered significant.
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and V179I to non-NRTIs. L210W contributes to resis-
tance to NRTIs, and K101Q causes low-level reduction
in susceptibility to non-NRTIs. However, the only muta-
tion known to be associated with resistance to NRTIs
was V118I.
Six of the 44 (13.6%) HIV-1 strains had mutations for
resistance to PIs and non-NRTIs, and one (2.3%) was
resistant to both NRTIs and non-NRTIs. Five strains
(11.4%) cumulated mutations to PIs, and three (6.8%)
cumulated mutations to non-NRTIs (Table 2).
Discussion
The prevalence of antibodies to HIV was 6.1%, with no
significant difference between 2005 and 2008 or by age
group. Although few data are available for Gabon, the
prevalence of antibodies to HIV between 1986 and 1989
was about 2.0% in the general population of Libreville
[17]. More recent studies on populations at risk in
Gabon showed a seroprevalence of 4.5% among manga-
nese miners and 7.5% in the general population living
close to Cameroon [7,9].
Of note, migrant populations and pregnant women
had higher seroprevalences than miners in Gabon; this
finding might be due to the geographic location of sam-
pling. The low seroprevalence among manganese miners
might be due to containment of this semi-rural popula-
tion, whereas migrant populations and pregnant women
are more representative of the general urban population.
Furthermore, the mining company educated workers
about HIV transmission, perhaps resulting in a ‘healthy
worker effect’. Similar findings were made in Cameroon
in 2004, with seroprevalences of 4.0% and 6.7% in rural
and urban populations [18]. In the Central African
Republic in 2006, a prevalence of 6.2% was found in
Bangui and 7.9% for the rest of country, with a seropre-
valence almost twice as high among women than men
[19].
Our results show that widely genetically diverse HIV-1
strains are circulating among untreated pregnant
women in Gabon, including pure subtypes (A, D, F, G,
H), a unique recombinant form (CRF02_AG) and com-
plex recombinant forms (CRF06_cpx, CRF11_cpx). At
least eight viral lineages have been observed, confirming
the results of previous studies in central Africa [7-10].
As a number of strains remained unclassified, genetic
diversity in Gabon is probably even greater, with com-
plex mosaic compositions. A wide genetic diversity of
circulating strains was also reported in the Democratic
Republic of the Congo and Cameroon [20,21]. We con-
firmed that CRF02_AG is still the most prevalent HIV-1
subtype throughout Gabon. This subtype was wide-
spread in west Africa a few years ago and is now present
in central Africa [22].
The geographic distribution of HIV subtypes is chan-
ging constantly, with the greatest genetic diversity of
HIV-1 in sub-Saharan Africa [23]. A preliminary study
i nt h eD e m o c r a t i cR e p u b l i co ft h eC o n g od e t e r m i n e d
pure subtypes of two HIV strains, and further investiga-
tions revealed a combination of several subtypes [24]. In
Table 2 Minor and major resistance-associated mutations
to protease inhibitors (PIs), nucleoside reverse
transcriptase inhibitors (NRTIs) and non-NRTIs of HIV-1
strains from untreated pregnant women in Gabon
Subtype n/N PIs NRTIs non-NRTIs
A 2/21 L10V - V106I, V179I
1/21 - L210W* E138A
2/21 - - V179I
16/21 -/ND -/ND -/ND
D 1/1 - - V179I
F 3/5 L10V - -
2/5 - - -
G 1/11 L10I ND ND
1/11 L10I, V11I ND ND
1/11 L10I, V11I, M46I* ND ND
1/11 - V118I -
1/11 - - A98S
2/11 - - V179E
4/11 - -/ND -/ND
H 2/2 -/ND - -
CRF02_AG 2/50 L10I - -
2/50 L10V - -
1/50 L10V, L33F --
1/50 L10V, T74S - -
2/50 E35G - -
1/50 M46I* - V90I
1/50 - T69S -
2/50 - - V90I
1/50 - - V90I, V179I
1/50 - - K101Q
1/50 - - K103R
2/50 - - V179I
33/50 - -/ND -/ND
CRF06_cpx 2/2 - - -
CRF11_cpx 1/2 L10I - -
1/2 - - -
Und 3/13 L10I - -
1/13 L10I - V106I
2/13 L10V -/ND -/ND
1/13 L10V - V179I
1/13 L10I, A71T - V179I
1/13 - A62V -
1/13 - V118I -
3/13 - - -
n, number of HIV-1 strains with resistance-associated mutations to PIs, NRTIs
and non-NRTIs; in boldface, major mutation; -, no mutation; ND, not done; *,
major mutation according to the list of investigations on transmitted ARVs
resistance-associated mutations in untreated individuals [16]
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to be far more complex than previously described, indi-
cating evolution of unique forms into complex combina-
tions [25]. Recombinant forms were reported to have
greater replicative capacity in vitro than the pure sub-
types from which they derived [26]. In our study, the
viral load of HIV-1 strains among untreated pregnant
women was high, suggesting a potentially critical role of
dual infections in vivo, as the attained HIV viral load
could limit the frequency of inter-subtype recombina-
tion [27].
Vergne et al. reported resistance to ARVs among
patients in Gabon followed up for HIV infection. No
other studies in this country have addressed direct
effects on the effectiveness of the most frequently used
ARVs in HIV-1 treatment. As expected, high frequencies
of polymorphism mutations were found in the P and RT
coding regions, which do not affect the three classes of
ARVs. Even in HIV-1 strains from untreated patients,
mutations associated with susceptibility to PIs, NRTIs
and non-NRTIs were observed. The L33F and M46I
mutations reduce susceptibility to PIs, except for saqui-
navir/r; L210W confers low-level resistance to several
NRTIs, except for lamivudine and emtricitabine; V118I
induces low-level resistance to lamivudine and K101Q
causes a low-level reduction in susceptibility to non-
NRTIs. These findings confirm resistance to HIV drugs
among untreated patients infected with non-B subtypes,
even though these drugs were introduced in Gabon rela-
tively recently.
Some ARVs resistance-associated mutations occur
commonly without selective pressure at highly poly-
morphic positions; these polymorphic mutations should
therefore not be considered in surveillance of trans-
mitted resistance to ARVs [16], as their inclusion leads
to inflated estimates. We found that 2.8% were major
mutations for resistance to PIs (1.9%) and NRTIs (0.9%),
providing little evidence for transmitted resistance to
ARVs among untreated pregnant women in central
Africa.
In the present study, we evaluated resistance in 107
samples obtained from strains in the active phase of viral
replication, representing about the half of the HIV-posi-
tive women. As these samples contain strains from all
r e g i o n so fG a b o n ,t h e yg i v ea no v e r a l lp i c t u r eo fn a t u r a l
ARVs resistance-associated mutations in this population.
We cannot exclude the possibility that other ARVs resis-
tance-associated mutations were present among strains
from samples not evaluated here. Therefore, the true
level of resistance might be underestimated, and epide-
miological studies should be conducted in the general
population each year to follow-up the circulating sub-
types of the HIV strains and to evaluate the emergence of
new ARVs resistance-associated mutations.
The emergence of strains with both minor and major
mutations for one or several classes of ARVs poses a
real problem, especially for the introduction of new
ARVs or switch therapy for HIV-infected patients.
Furthermore, the risk for resistance to ARVs treatment
might be exacerbated by cumulated mutations. Although
experts have dismissed the relevance of changes related
to polymorphic mutations of non-B subtypes, low-to-
moderate resistance to HIV drugs has been reported in
neighboring central African countries in which high
HIV diversity was found [28,29].
Conclusions
A high prevalence of antibodies to HIV, broad genetic
diversity and increased resistance to ARVs among
untreated pregnant women in Gabon demonstrate that
the epidemic features are now similar to those in other
central African countries. Moreover, our findings high-
light the potential consequences for molecular diagnosis
and follow-up of HIV-infected patients. Without control
of the HIV-1 load by ARVs treatment, viruses replicate
actively, increasing polymorphism or accumulated minor
mutations among these circulating strains. Thus, these
mutations can promote the transmission of strains resis-
tant to ARVs. Regular monitoring of the dynamics of
HIV-1 in this country must therefore continue, and
there is an urgent need to assess the impact of these
mutations on the effectiveness of ARVs therapy.
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